Biomea Fusion BMEA Stock
Biomea Fusion Price Chart
Biomea Fusion BMEA Financial and Trading Overview
| Biomea Fusion stock price | 1.3 USD |
| Previous Close | 1.38 USD |
| Open | 1.37 USD |
| Bid | 1.01 USD x 200 |
| Ask | 1.72 USD x 200 |
| Day's Range | 1.33 - 1.43 USD |
| 52 Week Range | 0.87 - 3.08 USD |
| Volume | 1.08M USD |
| Avg. Volume | 1.51M USD |
| Market Cap | 100.5M USD |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.55 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 6.83 USD |
BMEA Valuation Measures
| Enterprise Value | 57.04M USD |
| Trailing P/E | N/A |
| Forward P/E | -1.2602681 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 5.366795 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | -0.9 |
Trading Information
Biomea Fusion Stock Price History
| Beta (5Y Monthly) | N/A |
| 52-Week Change | -10.96% |
| S&P500 52-Week Change | 27.69% |
| 52 Week High | 3.08 USD |
| 52 Week Low | 0.87 USD |
| 50-Day Moving Average | 1.55 USD |
| 200-Day Moving Average | 1.5 USD |
BMEA Share Statistics
| Avg. Volume (3 month) | 1.51M USD |
| Avg. Daily Volume (10-Days) | 1.1M USD |
| Shares Outstanding | 72.3M |
| Float | 67.44M |
| Short Ratio | 9.1 |
| % Held by Insiders | 7.16% |
| % Held by Institutions | 38.87% |
| Shares Short | 14.4M |
| Short % of Float | 24.29% |
| Short % of Shares Outstanding | 19.91% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | March 31, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -79.31% |
| Return on Equity (ttm) | -189.43% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | -63382000 USD |
| Net Income Avi to Common (ttm) | -44950000 USD |
| Diluted EPS (ttm) | -0.55 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 44.69M USD |
| Total Cash Per Share (mrq) | 0.62 USD |
| Total Debt (mrq) | 1.24M USD |
| Total Debt/Equity (mrq) | 6.62 USD |
| Current Ratio (mrq) | 4.984 |
| Book Value Per Share (mrq) | 0.259 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -56373000 USD |
| Levered Free Cash Flow (ttm) | -32863624 USD |
Profile of Biomea Fusion
| Country | United States |
| State | CA |
| City | San Carlos |
| Address | 1599 Industrial Road |
| ZIP | 94070 |
| Phone | 650 980 9099 |
| Website | https://biomeafusion.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 41 |
Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral drugs to treat patients with diabetes and obesity. It's lead clinical program's drug candidates are COVALENT-111 and COVALENT-112, which has completed Phase II clinical trials of icovamenib for the treatment of Type 1 and Type 2 diabetes; COVALENT-211, which is in Phase II clinical trial of icovamenib for treating insulin-deficient type 2 diabetes; and COVALENT-212, which is in Phase II clinical trial of icovamenib for the treatment of type 2 diabetes. The company is also developing BMF-650, which is in Phase I glucagon-like peptide-131 clinical trial for the treatment of obesity. The company was incorporated in 2017 and is headquartered in San Carlos, California.
Q&A For Biomea Fusion Stock
What is a current BMEA stock price?
Biomea Fusion BMEA stock price today per share is 1.3 USD.
How to purchase Biomea Fusion stock?
You can buy BMEA shares on the Tech Market Large exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Biomea Fusion?
The stock symbol or ticker of Biomea Fusion is BMEA.
Which industry does the Biomea Fusion company belong to?
The Biomea Fusion industry is Biotechnology.
How many shares does Biomea Fusion have in circulation?
The max supply of Biomea Fusion shares is 72.3M.
What is Biomea Fusion Price to Earnings Ratio (PE Ratio)?
Biomea Fusion PE Ratio is now.
What was Biomea Fusion earnings per share over the trailing 12 months (TTM)?
Biomea Fusion EPS is -0.55 USD over the trailing 12 months.
Which sector does the Biomea Fusion company belong to?
The Biomea Fusion sector is Healthcare.
Biomea Fusion BMEA included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| US Tech Composite IXIC | 26853.98 USD — |
-0.89
|
8.32B USD — | 26769.16 USD — | 27130.88 USD — | — - | 8.32B USD — |
| Stlmt ID US Tech Biotechnology NBX | 3995.9 USD — |
-4.37
|
— — | 4555.41 USD — | 4917.8 USD — | — - | — — |
| US Tech Global Select Market Com NQGS | 13180.97 USD — |
-0.87
|
— — | 13139.79 USD — | 13316.81 USD — | — - | — — |
| US Tech Biotechnology NBI | 5807.22 USD — |
+1.87
|
— — | 5685.34 USD — | 5809.82 USD — | — - | — — |
| US Tech Health Care IXHC | 1133.51 USD — |
+1.54
|
— — | 1113.35 USD — | 1133.95 USD — | — - | — — |
- {{ link.label }} {{link}}